Wall Street analysts expect Agenus Inc (NASDAQ:AGEN) to report ($0.26) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Agenus’ earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.27). Agenus posted earnings per share of ($0.33) in the same quarter last year, which indicates a positive year-over-year growth rate of 21.2%. The business is expected to report its next quarterly earnings report on Monday, November 2nd.
On average, analysts expect that Agenus will report full year earnings of ($1.02) per share for the current financial year, with EPS estimates ranging from ($1.12) to ($0.97). For the next financial year, analysts forecast that the business will report earnings of ($1.07) per share, with EPS estimates ranging from ($1.21) to ($0.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Agenus.
Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). The firm had revenue of $26.95 million during the quarter, compared to analysts’ expectations of $9.33 million.
Institutional investors and hedge funds have recently made changes to their positions in the business. Swiss National Bank increased its holdings in Agenus by 9.8% in the 2nd quarter. Swiss National Bank now owns 245,300 shares of the biotechnology company’s stock valued at $964,000 after purchasing an additional 21,800 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of Agenus by 56.0% during the 1st quarter. Two Sigma Advisers LP now owns 719,100 shares of the biotechnology company’s stock worth $1,762,000 after purchasing an additional 258,100 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of Agenus by 39.2% during the 2nd quarter. New York State Common Retirement Fund now owns 126,800 shares of the biotechnology company’s stock worth $498,000 after purchasing an additional 35,700 shares during the last quarter. Chicago Equity Partners LLC lifted its position in Agenus by 61.4% in the first quarter. Chicago Equity Partners LLC now owns 157,508 shares of the biotechnology company’s stock valued at $386,000 after acquiring an additional 59,913 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in Agenus by 137.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 50,378 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 29,154 shares during the last quarter. 49.07% of the stock is currently owned by institutional investors.
AGEN opened at $5.14 on Wednesday. The stock has a market cap of $919.03 million, a price-to-earnings ratio of -4.39 and a beta of 2.08. The stock’s 50 day moving average price is $3.92 and its 200-day moving average price is $3.24. Agenus has a one year low of $1.82 and a one year high of $5.63.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Recommended Story: Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.